Orionis Biosciences Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Employees
  • 39
Employees
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $25.5M
Latest Deal Amount
  • Investors
  • 10

Orionis Biosciences General Information

Description

Developer of therapeutic agents intended to treat cancer. The company integrates multiple advances in molecular and cellular interaction discovery technologies, protein engineering, and genome-scale mapping of cellular fingerprints of drug interactions with relational data science, machine learning, and structure or activity-based design of drug ligand-protein interactions to offer a drug discovery engine, thereby enabling clinicians to treat cancer and other diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Discovery Tools (Healthcare)
Primary Office
  • 950 Winter Street
  • Waltham, MA 02451
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orionis Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 21-Mar-2018 $25.5M 000.00 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 25-Oct-2015 00.000 00.000 Completed Startup
To view Orionis Biosciences’s complete valuation and funding history, request access »

Orionis Biosciences Patents

Orionis Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200308244-A1 Therapeutic interferon alpha 1 proteins Pending 28-Mar-2019 000000000
CA-3125527-A1 Particle based small molecule-protein complex trap Pending 20-Dec-2018 000000000
EP-3899539-A1 Particle based small molecule-protein complex trap Pending 20-Dec-2018 000000000
EP-3890773-A1 Modulation of dendritic cell lineages Pending 08-Nov-2018 000000000
CA-3118892-A1 Modulation of dendritic cell lineages Pending 08-Nov-2018 C07K14/56

Orionis Biosciences Executive Team (4)

Name Title Board Seat Contact Info
Nikolai Kley Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Jan Tavernier Ph.D Co-Founder & Chief Technology Officer
Riccardo Sabatini Ph.D Chief Data Scientist
Andrew Littlehale Vice President of Finance
To view Orionis Biosciences’s complete executive team members history, request access »

Orionis Biosciences Board Members (4)

Name Representing Role Since
Griet Vanpoucke Ph.D Self Board Member 000 0000
Matias de Tezanos PeopleFund Board Member 000 0000
Nikolai Kley Ph.D Orionis Biosciences Co-Founder, Chief Executive Officer, President & Board Member 000 0000
Steven Gullans Ph.D Excel Venture Management Board Member 000 0000
To view Orionis Biosciences’s complete board members history, request access »

Orionis Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Orionis Biosciences Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andrew Wang Angel (individual) Minority 000 0000 000000 0
Empire Angels Angel Group Minority 000 0000 000000 0
Ihar Mahaniok Angel (individual) Minority 000 0000 000000 0
Peter Gonzalez Angel (individual) Minority 000 0000 000000 0
Pranav Amin Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »